FATE

Healthcare Biotechnology

Fate Therapeutics, Inc.

$2.32

+0.05 +2.20% today

Price History

Not enough data

Key Stats

Market Cap

277.98M

Avg Volume

1.92M

EPS

-$1.05

52W High

$3.23

52W Low

$0.95

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-2.40

P/B Ratio

1.76

P/S Ratio

42.83

EV/EBITDA

-1.66

EV/Revenue

30.80

Margins

Gross Margin 0.0%

Operating Margin (1495.4%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

9.2%

Return on Equity

(60.8%)

Return on Assets

(26.2%)

Liquidity & Leverage

Current Ratio

4.85

Quick Ratio

4.75

Debt / Equity

0.49

Total Cash

153.77M

Total Debt

75.67M

About

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.